Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease

키워드

참고문헌 (83)

1. Isakova T, "Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease", Kidney Int, 79, pp.1370~1378 (2011)[DOI]
2. Moe S, "Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)", Kidney Int, 69, pp.1945~1953 (2006)[DOI]
3. Jørgensen HS, "Traditional and nontraditional risk factors for osteoporosis in CKD", Calcif Tissue Int, 108, pp.496~511 (2021)[DOI]
4. Vilaca T, "Risks of hip and nonvertebral fractures in patients with CKD G3a-G5D : A systematic review and meta-analysis", Am J Kidney Dis, 76, pp.521~532 (2020)[DOI]
5. Tentori F, "High rates of death and hospitalization follow bone fracture among hemodialysis patients", Kidney Int, 85, pp.166~173 (2014)[DOI]
6. Barrera-Baena P, "Serum phosphate is associated with increased risk of bone fragility fractures in hemodialysis patients", Nephrol Dial Transplant, 39, pp.618~626 (2023)[DOI]
7. Evenepoel P, "Bone biopsy practice patterns across Europe : The European renal osteodystrophy initiative-a position paper", Nephrol Dial Transplant, 32, pp.1608~1613 (2017)[DOI]
8. Kidney Disease : Improving Global Outcomes(KDIGO)CKD-MBD Update Work Group, "KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder(CKD-MBD)", Kidney Int Suppl(2011), 7, pp.1~59 (2017)[DOI]
9. Aguilar A, "Pathophysiology of bone disease in chronic kidney disease : From basics to renal osteodystrophy and osteoporosis", Front Physiol, 14, pp.1177829~ (2023)[DOI]
10. Ben-awadh AN, "Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes", Endocrinology, 155, pp.2797~2809 (2014)[DOI]
11. Evenepoel P, "Parathyroid hormone metabolism and signaling in health and chronic kidney disease", Kidney Int, 90, pp.1184~1190 (2016)[DOI]
12. Kritmetapak K, "Chemical Characterization and Quantification of Circulating Intact PTH and PTH Fragments by High-Resolution Mass Spectrometry in Chronic Renal Failure", Clin Chem, 67, pp.843~853 (2021)[DOI]
13. Souberbielle JC, "Inter-method variability in PTH measurement : Implication for the care of CKD patients", Kidney Int, 70, pp.345~350 (2006)[DOI]
14. Sprague SM, "Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis", Am J Kidney Dis, 67, pp.559~566 (2016)[DOI]
15. D'Amour P, "Amino-terminal form of parathyroid hormone(PTH)with immunologic similarities to hPTH(1-84)is overproduced in primary and secondary hyperparathyroidism", Clin Chem, 49, pp.2037~2044 (2003)[DOI]
16. Arakawa T, "Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia", Clin J Am Soc Nephrol, 1, pp.525~531 (2006)[DOI]
17. Ursem SR, "Oxidation of parathyroid hormone", Clin Chim Acta, 506, pp.84~91 (2020)[DOI]
18. Ursem SR, "Non-oxidized parathyroid hormone(PTH)measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease", Kidney Int, 99, pp.1173~1178 (2021)[DOI]
19. Cavalier E, "Unveiling a new era with liquid chromatography coupled with mass spectrometry to enhance parathyroid hormone measurement in patients with chronic kidney disease", Kidney Int, 105, pp.338~346 (2024)[DOI]
20. Wesseling-Perry K, "The calcemic response to continuous parathyroid hormone(PTH)(1-34)infusion in end-stage kidney disease varies according to bone turnover : A potential role for PTH(7-84)", J Clin Endocrinol Metab, 95, pp.2772~2780 (2010)[DOI]
21. Quarles LD, "Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia", J Clin Endocrinol Metab, 75, pp.145~150 (1992)[DOI]
22. Evenepoel P, "Skeletal parathyroid hormone hyporesponsiveness : A neglected, but clinically relevant reality in chronic kidney disease", Curr Opin Nephrol Hypertens, 33, pp.383~390 (2024)[DOI]
23. Yamamoto S, "Alkaline phosphatase and parathyroid hormone levels : International variation and associations with clinical outcomes in the DOPPS", Kidney Int Rep, 9, pp.863~876 (2024)[DOI]
24. Evenepoel P, "Lower bone turnover and skeletal PTH responsiveness in Japanese compared to European patients on hemodialysis", J Clin Endocrinol Metab, 107, pp.e4350~e4359 (2022)[DOI]
25. Sawaya BP, "Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease", Kidney Int, 64, pp.737~742 (2003)[DOI]
26. Schini M, "Bone turnover markers : Basic biology to clinical applications", Endocr Rev, 44, pp.417~473 (2023)[DOI]
27. Vasikaran S, "International osteoporosis foundation and international federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis", Clin Chem Lab Med, 49, pp.1271~1274 (2011)[DOI]
28. Tridimas A, "Assessing bone formation in patients with chronic kidney disease using procollagen type I N-terminal propeptide(PINP) : The choice of assay makes a difference", Ann Clin Biochem, 58, pp.528~536 (2021)[DOI]
29. Yamada S, "Utility of serum tartrate-resistant acid phosphatase(TRACP5b)as a bone resorption marker in patients with chronic kidney disease : Independence from renal dysfunction", Clin Endocrinol(Oxf), 69, pp.189~196 (2008)[DOI]
30. Neto R, "Sclerostin and DKK1circulating levels associate with low bone turnover in patients with chronic kidney disease Stages 3 and 4", Clin Kidney J, 14, pp.2401~2408 (2021)[DOI]
31. Malluche HH, "Renal osteodystrophy in the first decade of the new millennium : Analysis of 630 bone biopsies in black and white patients", J Bone Miner Res, 26, pp.1368~1376 (2011)[DOI]
32. Carbonara CEM, "Renal osteodystrophy and clinical outcomes : Data from the Brazilian Registry of Bone Biopsies-REBRABO", J Bras Nefrol, 42, pp.138~146 (2020)[DOI]
33. Kidney Disease: Improving Global Outcomes (KDIGO)CKD-MBD Work Group, "KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)", Kidney Int Suppl, pp.S1~S130 (2009)[DOI]
34. Salam S, "Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy", J Am Soc Nephrol, 29, pp.1557~1565 (2018)[DOI]
35. Lima F, "Serum bone markers in ROD patients across the spectrum of decreases in GFR:Activin A increases before all other markers", Clin Nephrol, 91, pp.222~230 (2019)[DOI]
36. Jørgensen HS, "Diagnostic accuracy of noninvasive bone turnover markers in renal osteodystrophy", Am J Kidney Dis, 79, pp.667~676 (2022)[DOI]
37. Domrongkitchaiporn S, "Bone mineral density and histology in distal renal tubular acidosis", Kidney Int, 59, pp.1086~1093 (2001)[DOI]
38. Carbonara CEM, "Effect of aluminum accumulation on bone and cardiovascular risk in the current era", PLoS One, 18, pp.e0284123~ (2023)[DOI]
39. Nickolas TL, "Bone mass and microarchitecture in CKD patients with fracture", J Am Soc Nephrol, 21, pp.1371~1380 (2010)[DOI]
40. Nakagawa Y, "Interrelationships between sclerostin, secondary hyperparathyroidism, and bone metabolism in patients on hemodialysis", J Clin Endocrinol Metab, 107, pp.e95~e105 (2022)[DOI]
41. Jørgensen HS, "Bone turnover markers are associated with bone density, but not with fracture in end stage kidney disease : A cross-sectional study", BMC Nephrol, 18, pp.284~ (2017)[DOI]
42. Xu Y, "Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease", Clin Kidney J, 14, pp.2213~2220 (2021)[DOI]
43. Geng S, "Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease", Osteoporos Int, 30, pp.2019~2025 (2019)[DOI]
44. Coco M, "Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone", Am J Kidney Dis, 36, pp.1115~1121 (2000)[DOI]
45. Danese MD, "PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis", Am J Kidney Dis, 47, pp.149~156 (2006)[DOI]
46. Matias PJ, "Bone fracture risk factors in prevalent hemodialysis patients", J Bone Miner Metab, 38, pp.205~212 (2020)[DOI]
47. Iimori S, "Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-a single-center cohort study", Nephrol Dial Transplant, 27, pp.345~351 (2012)[DOI]
48. Maruyama Y, "A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan", Nephrol Dial Transplant, 29, pp.1532~1538 (2014)[DOI]
49. Coen G, "Bone turnover, osteopenia and vascular calcifications in hemodialysis patients. A histomorphometric and multislice CT study", Am J Nephrol, 29, pp.145~152 (2009)[DOI]
50. London GM, "Arterial calcifications and bone histomorphometry in end-stage renal disease", J Am Soc Nephrol, 15, pp.1943~1951 (2004)[DOI]
51. Sumida K, "Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass : A prospective study", Osteoporos Int, 27, pp.1441~1450 (2016)[DOI]
52. Yamamoto J, "Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone : A pilot study", Ther Apher Dial, 24, pp.146~153 (2020)[DOI]
53. Mitsopoulos E, "Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients:A pilot study", Am J Nephrol, 36, pp.238~244 (2012)[DOI]
54. Chen CL, "Effects of denosumab and calcitriol on severe secondary hyperparathyroidism in dialysis patients with low bone mass", J Clin Endocrinol Metab, 100, pp.2784~2792 (2015)[DOI]
55. Torregrosa JV, "Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis", Kidney Int, (Suppl), pp.S88~S90 (2003)[DOI]
56. Iseri K, "Long-term effect of denosumab on bone disease in patients with CKD", Clin J Am Soc Nephrol, 18, pp.1195~1203 (2023)[DOI]
57. Iseri K, "Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients : A randomized, controlled trial", J Bone Miner Res, 34, pp.1014~1024 (2019)[DOI]
58. Miller PD, "Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease", J Bone Miner Res, 37, pp.1437~1445 (2022)[DOI]
59. Bilezikian JP, "Abaloparatide in patients with mild or moderate renal impairment : Results from the ACTIVE phase 3 trial", Curr Med Res Opin, 35, pp.2097~2102 (2019)[DOI]
60. Miller PD, "Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment", Osteoporos Int, 18, pp.59~68 (2007)[DOI]
61. Miller PD, "Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method : A pooled analysis of nine clinical trials", J Bone Miner Res, 20, pp.2105~2115 (2005)[DOI]
62. Ishani A, "Renal function and rate of hip bone loss in older men : The Osteoporotic Fractures in Men Study", Osteoporos Int, 19, pp.1549~1556 (2008)[DOI]
63. Hara T, "Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D", Cochrane Database Syst Rev, 7, pp.CD013424~ (2021)[DOI]
64. Malluche HH, "Treatment of bone loss in CKD5D : Better survival in patients with non-high bone turnover", Clin Nephrol, 98, pp.219~228 (2022)[DOI]
65. Jørgensen HS, "Vascular calcification of the abdominal aorta has minimal impact on lumbar spine bone density in patients with chronic kidney disease", Bone, 162, pp.116482~ (2022)[DOI]
66. Robinson DE, "Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease : A binational cohort analysis", J Bone Miner Res, 36, pp.820~832 (2021)[DOI]
67. Ali MS, "Alendronate use and bone mineral density gains in women with moderate-severe(stages 3B-5)chronic kidney disease : An open cohort multivariable and propensity score analysis from Funen, Denmark", Arch Osteoporos, 15, pp.81~ (2020)[DOI]
68. Bergner R, "Treatment of reduced bone density with ibandronate in dialysis patients", J Nephrol, 21, pp.510~516 (2008)
69. Iseri K, "Elimination of intravenous alendronate by hemodialysis : A kinetic study", Hemodial Int, 23, pp.466~471 (2019)[DOI]
70. Bergner R, "Elimination of intravenously administered ibandronate in patients on haemodialysis : A monocentre open study", Nephrol Dial Transplant, 17, pp.1281~1285 (2002)[DOI]
71. Block GA, "A single-dose study of denosumab in patients with various degrees of renal impairment", J Bone Miner Res, 27, pp.1471~1479 (2012)[DOI]
72. Hiramatsu R, "Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab : A 2-year observational study", Nephrol Dial Transplant, 36, pp.1900~1907 (2021)[DOI]
73. Kato K, "Long-term effects of denosumab on bone mineral density and turnover markers in patients undergoing hemodialysis", J Bone Miner Metab, 42, pp.264~270 (2024)[DOI]
74. Kim H, "Effect of denosumab on bone health, vascular calcification, and health-related quality of life in hemodialysis patients with osteoporosis : A prospective observational study", J Clin Med, 13, pp.1462~ (2024)[DOI]
75. Bird ST, "Severe hypocalcemia with denosumab among older female dialysis-dependent patients", JAMA, 331, pp.491~499 (2024)[DOI]
76. Saito T, "One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis : An observational study", Calcif Tissue Int, 112, pp.34~44 (2023)[DOI]
77. Cosman F, "Romosozumab treatment in postmenopausal women with osteoporosis", N Engl J Med, 375, pp.1532~1543 (2016)[DOI]
78. Saag KG, "Romosozumab or alendronate for fracture prevention in women with osteoporosis", N Engl J Med, 377, pp.1417~1427 (2017)[DOI]
79. Ingle BM, "Changes in bone mass and bone turnover following distal forearm fracture", Osteoporos Int, 10, pp.399~407 (1999)[DOI]
80. Gentry J, "Serum phosphorus adds to value of serum parathyroid hormone for assessment of bone turnover in renal osteodystrophy", Clin Nephrol, 86, pp.9~17 (2016)[DOI]
81. Pereira L, "Evaluation of renal osteodystrophy and serum bone-related biomarkers in a peritoneal dialysis population", J Bone Miner Res, 37, pp.1689~1699 (2022)[DOI]
82. Vrist MH, "Bone turnover, mineralization, and volume estimated by 18F-sodium fluoride PET", CT and biomarkers in chronic kidney disease : Mineral and bone disorder compared with bone biopsy, 2022, pp.53, 490~502
83. de Oliveira RA, "Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease", Kidney Int, 87, pp.1039~1045 (2015)[DOI]

관련 논문AI추천